efficacy and safety study were switched to RGB-02 treatment following the first two chemotherapy cycles. Endpoints assessed were related to the change in ANC count in healthy volunteers, duration of severe neutropenia (DSN; ANC < 0.5 x10 9 /L) in the comparative efficacy and safety study, as well as safety data including immunogenicity collected in each clinical study. Results: None of the PD endpoints showed any difference following the cross-over in the comparative PK/PD studies. The mean DSN values after the therapy switch were similar to the values prior to the switch and the switched arm (mean DSN: 0.6) did not show decreased efficacy compared to the arm received RGB-02 from the first cycle (mean DSN: 0.9). Safety results, including immunogenicity of the 3 studies did not reveal any negative impact of the treatment switch. Conclusions: Treatment switch from Neulasta V R to RGB-02 can be considered safe while maintaining the therapeutic effect of pegfilgrastim therapy. Clinical trial identification: EudraCT: 2011-001737-17; EudraCT: 2016-005051-25; EudraCT: 2013-003166-14 had breast cancer, 69% had prior tumor-related therapy and 20% prior Ctx). Of those receiving prior Ctx, 39% needed neutropenia treatment. Of the 1914 pts, pegfilgrastim was used as primary and secondary prophylaxis in 78% and 22%, respectively (primary endpoint). Primary prophylaxis was more frequent than secondary in the HR (87 vs 13% of 936 pts) and MR (73 vs 27% of 835 pts) groups. At a pt level, overall FN rate was 8% and varied across tumors: gastric 12%, breast 9%, lung 7%, lymphoma 8% and ovarian 3%. Across these tumors, the number of cycles with FN were 1.9%, 3.2%, 1.9%, 1.9%, 2.1% and 0.6%, respectively. Overall, 2% had a dose reduction or therapy switch due to FN. In breast cancer, dose reductions or therapy switches occurred in 1% of pts receiving primary prophylaxis and 3% receiving secondary prophylaxis. Conclusions: In this study of pts receiving pegfilgrastim prophylaxis in routine German practice, the majority of HR pts with overall FN risk of > 20% were treated with primary pegfilgrastim prophylaxis in concordance with the EORTC guidelines. Primary prophylaxis with pegfilgrastim was associated with a low FN incidence and a low rate of dose reductions and treatment delays. Background: Many patients experience toxicity from chemotherapy that can negatively impact their health-related quality of life (HRQoL), but side effects often go undetected by health care personnel. Hematologic toxicity (HT) is the main dose-limiting toxicity of chemotherapy. Our aim was to investigate whether patients who experienced severe HT had more negative changes in HRQoL than those who did not. If so, blood counts could represent a simple and objective method for identifying patients at risk of severely impaired HRQoL who may benefit from more supportive care during the treatment period. Methods: Data from two phase III trials of first-line chemotherapy in advanced nonsmall-cell lung cancer (NSCLC) were analyzed (n ¼ 873). Blood counts were measured weekly. We categorized patients as having severe (CTCAE grade 3-4) or nonsevere (grade 0-2) HT during the first chemotherapy cycle. HRQoL was reported on the EORTC QLQ-C30 and LC13 before and at the end of the cycle. The primary endpoints were changes in global quality of life, fatigue, nausea/vomiting and dyspnea (LC13). Mean differences of 5-10 points was considered to represent a small clinical difference. Results: Of the 766 patients with complete data set, 177 (23%) developed severe HT during the first chemotherapy cycle. Severe neutropenia and thrombocytopenia was observed in 149 (19%) and 67 (9%) patients, respectively, while only three (0.4%) patients had severe anemia. Changes in fatigue and nausea/ vomiting were significantly worse for patients experiencing severe compared to patients with non-severe HT (difference in mean change of 4.9 points; p ¼ 0.01, and 6.4 points; p ¼ 0.01, respectively), but this association was limited to neutropenia, not thrombocytopenia or anemia. There were no significant associations between HT and global quality of life or dyspnea (difference in mean change of 2.1 points; p ¼ 0.28, and 3.3 points; p ¼ 0.053, respectively). Conclusions: Patients developing severe HT had worse changes in two out of four HRQoL endpoints, but the association was not strong enough to use blood counts to identify patients who experience deterioration of HRQoL during chemotherapy. Background: DN has shown superiority in delaying skeletal related events when given q4w over zoledronic (ZA) acid given q4w. Newer data have shown that ZA given q12w is non-inferior to ZA q4w. The primary endpoint of REDUSE is to show non-inferiority
Background: The EORTC guidelines recommend primary prophylaxis with G-CSF when the overall risk of febrile neutropenia (FN) is 20% (high risk [HR] ) or if the chemotherapy FN risk is 10-20% (medium risk [MR] ) with additional patient (pt)-related risk factors. This study assessed the acceptance of these guidelines in German routine practice. Methods: Non-interventional study of pegfilgrastim use in pts receiving Ctx for solid tumors or lymphomas (2007-2014 in 123 German centers). Pts were >18 yrs, had breast, ovarian, gastric, prostate or lung cancer, or aggressive lymphoma, EORTCdefined FN risk 10%, and prophylactic pegfilgrastim use. Primary endpoint: proportion of pts receiving pegfilgrastim as primary (prior to neutropenia) or secondary (following neutropenia occurrence) prophylaxis. Results: Data were available from 1914/2069 pts (average age 58 yrs, 79% female, 60% had breast cancer, 69% had prior tumor-related therapy and 20% prior Ctx). Of those receiving prior Ctx, 39% needed neutropenia treatment. Of the 1914 pts, pegfilgrastim was used as primary and secondary prophylaxis in 78% and 22%, respectively (primary endpoint). Primary prophylaxis was more frequent than secondary in the HR (87 vs 13% of 936 pts) and MR (73 vs 27% of 835 pts) groups. At a pt level, overall FN rate was 8% and varied across tumors: gastric 12%, breast 9%, lung 7%, lymphoma 8% and ovarian 3%. Across these tumors, the number of cycles with FN were 1.9%, 3.2%, 1.9%, 1.9%, 2.1% and 0.6%, respectively. Overall, 2% had a dose reduction or therapy switch due to FN. In breast cancer, dose reductions or therapy switches occurred in 1% of pts receiving primary prophylaxis and 3% receiving secondary prophylaxis. Conclusions: In this study of pts receiving pegfilgrastim prophylaxis in routine German practice, the majority of HR pts with overall FN risk of > 20% were treated with primary pegfilgrastim prophylaxis in concordance with the EORTC guidelines. Primary prophylaxis with pegfilgrastim was associated with a low FN incidence and a low rate of dose reductions and treatment delays. Background: Many patients experience toxicity from chemotherapy that can negatively impact their health-related quality of life (HRQoL), but side effects often go undetected by health care personnel. Hematologic toxicity (HT) is the main dose-limiting toxicity of chemotherapy. Our aim was to investigate whether patients who experienced severe HT had more negative changes in HRQoL than those who did not. If so, blood counts could represent a simple and objective method for identifying patients at risk of severely impaired HRQoL who may benefit from more supportive care during the treatment period. Methods: Data from two phase III trials of first-line chemotherapy in advanced nonsmall-cell lung cancer (NSCLC) were analyzed (n ¼ 873). Blood counts were measured weekly. We categorized patients as having severe (CTCAE grade 3-4) or nonsevere (grade 0-2) HT during the first chemotherapy cycle. HRQoL was reported on the EORTC QLQ-C30 and LC13 before and at the end of the cycle. The primary endpoints were changes in global quality of life, fatigue, nausea/vomiting and dyspnea (LC13). Mean differences of 5-10 points was considered to represent a small clinical difference. Results: Of the 766 patients with complete data set, 177 (23%) developed severe HT during the first chemotherapy cycle. Severe neutropenia and thrombocytopenia was observed in 149 (19%) and 67 (9%) patients, respectively, while only three (0.4%) patients had severe anemia. Changes in fatigue and nausea/ vomiting were significantly worse for patients experiencing severe compared to patients with non-severe HT (difference in mean change of 4.9 points; p ¼ 0.01, and 6.4 points; p ¼ 0.01, respectively), but this association was limited to neutropenia, not thrombocytopenia or anemia. There were no significant associations between HT and global quality of life or dyspnea (difference in mean change of 2.1 points; p ¼ 0.28, and 3.3 points; p ¼ 0.053, respectively). Conclusions: Patients developing severe HT had worse changes in two out of four HRQoL endpoints, but the association was not strong enough to use blood counts to identify patients who experience deterioration of HRQoL during chemotherapy. for DN q12w versus q4w (SSE). Here we present the data for the secondary endpoint hypocalcemia (HC). Methods: Patients with metastatic breast cancer (BC) or metastatic castration resistant prostate cancer (PC) (planned N ¼ 1380) were randomized 1:1 to receive DN q4w (Arm A) versus q12w (Arm B) after a 3-month induction phase with application q4w. All patients received vitamin D 400 U (ViD) and calcium (Ca) 500 mg daily. Measurement of serum-calcium was mandatory before each DN injection. This safety interim analysis was performed after 3.5 years of accrual. (N ¼ 634; BC N ¼ 351, PC N ¼ 283). Results: Patients who received at least 1 dose of DN were considered evaluable. HC was the most common side effect with 23.7% overall (BC 18.6%, PC 30.2%). While HC occurred in 31.6% in Arm A, the rate was 15.8% in Arm B. Grade 3/4 HC was rare (overall: 1.3%, all with PC). After 1 year of treatment, the incidence of HC was lower in both arms (A: 27.2%, B: 14.3%). Since HC improved in more patients in Arm B than Arm A whereas it got worse in Arm A compared to Arm B, a remarkable difference for HC was noticed between the two arms (Table) . Arm A: Denosumab q4w, Arm B: Denosumab q12w.
Conclusions: In our trial up to 30% of all patients treated with DN experienced HC in the q4w induction phase despite mandatory supplementation and measurement of ViD and Ca. This rate was considerably higher than reported in the registration trials of DN (PC 13.0%, BC 5.5%). After randomization the appearance of HC is remarkably lower in the q12w arm compared to q4w. This suggests that DN given q12w has a more favorable long time toxicity profile (HC) compared to DN q4w. Clinical trial identification: NCT02051218. Legal entity responsible for the study: Swiss Group for Clinical Cancer Research (SAKK). Background: Triple antiemetic therapy, such as a 5-HT3 receptor antagonist (5H3-RA), aprepitant and dexamethasone, is recommended for the prophylaxis of highly emetogenic chemotherapy induced nausea and vomiting in patients with breast cancer. In the present study, we aimed to verify whether adding metoclopramide to the triplet antiemetic therapy is superior to the triplet antiemetic therapy in preventing CINV in patients with breast cancer. Methods: A single-blind, randomized trial was performed on ninety-seven patients who received HEC among chemotherapy-naive patients with breast cancer. The visual analogue scale (VAS) utilized to detect nausea, and FLIE was used in order to determine its impact on the patients' quality of life. The patients were randomized to arm A(n:48, dexamethasone and 5HT3RA on day 1, aprepitant on day 1-3, and metoclopramide on days 1-5) and arm B (n:49, dexamethasone and 5HT3RA on day 1and aprepitant on day 1-3). The primary endpoint was complete response (CR) (no nausea, no vomiting, and no rescue medication) during the overall phase (days 1-5).
Results: The demographic and clinical features such as age, educational background, height and weight measurements were similar in both groups. The CR was found in twenty patients (45.8%) of the forty-eight patients in the arm A, while it was found in thirteen patients (26.5%) of the forty-nine patients in the arm B (p:0.038).The mean total FLIE score was 31.31 (SD: 20.5) in arm A, which was42.29 (SD: 26.4) in arm B (p:0.045). Conclusions: A triple or quadruple antiemetic combination is proposed to alleviate CINV for female patients with breast cancer treated with HEC. In patients receiving anthracycline-based chemotherapy, quadruple antiemetic therapy with dexamethasone, aprepitant, palonosetron and metoclorpropamide is associated with a significant CR and clinically relevant improvement in FLIE score, compared to dexamethasone, aprepitant and palonosetron. Therefore, a quadruple antiemetic combination including metpamid might be a treatment option for patients receiving highly emetogenic chemotherapy. Legal entity responsible for the study: Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
